Diagnostic value of cardiovascular biomarkers for cerebral–cardiac syndrome risk in acute ischemic stroke
-
By
-
Zegang Liu
-
Ying Zhao
-
Mei Wang
-
Chenwei Li
-
Xurong Zhu
-
Peirui Wang
-
Ke Wang
-
July 8, 2026
-
Clinical Scorecard: Evaluating Cardiovascular Biomarkers for Assessing Cerebral-Cardiac Syndrome Risk in Acute Ischemic Stroke Patients
At a Glance
| Category | Detail |
|---|
| Condition | Cerebral–cardiac syndrome (CCS) |
| Key Mechanisms | Brain-heart interaction following ischemic stroke leading to cardiac injuries. |
| Target Population | Patients with acute ischemic stroke (AIS). |
| Care Setting | Neurology department of a hospital. |
Key Highlights
- CCS occurred in 54.8% of AIS patients studied.
- BNP, DD, cTnI, Myo, and CK-MB levels were significantly elevated in CCS patients.
- Age, BNP, and Myo were identified as independent risk factors for CCS.
- The combined model of age, BNP, and Myo showed excellent diagnostic performance.
- Early diagnosis of CCS is crucial for timely intervention.
Guideline-Based Recommendations
Diagnosis
- Use of cardiovascular biomarkers such as BNP and Myo for CCS diagnosis.
Management
- Timely risk stratification and intervention for CCS in AIS patients.
Monitoring & Follow-up
- Regular assessment of cardiac biomarkers in AIS patients.
Risks
- CCS significantly increases morbidity and mortality in stroke patients.
Patient & Prescribing Data
Patients aged 18 and above diagnosed with acute ischemic stroke.
Focus on early identification of CCS to facilitate timely intervention.
Clinical Best Practices
- Implement routine screening for CCS in AIS patients.
- Utilize a combination of age and specific biomarkers for risk assessment.
Related Resources & Content
